Hillmen P, Munir T, Rawstron A, et al. Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy. ASH 59th Annual Meeting & Exhibition, abstract 428.
Toevoegen stamceltransplantatie aan lenalidomide-bortezomib-dexamethason verbetert PFS bij MM
aug 2022 | MM, Stamceltransplantatie